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ABSTRACT 
 
 
The interaction of the exocyst complex and SNARE proteins is essential in exocytosis, 
specifically to the tethering and fusion of secretory vesicles at the plasma membrane. While the 
specific mechanisms of vesicle trafficking are largely unknown, direct interactions have been 
found between the exocyst subunit Sec6p and the t-SNARE Sec9p.  To investigate a possible 
binding site for the two proteins, a recombinant S. cerevisiae Sec9p mutant, designed to disrupt 
binding with Sec6p, was cloned, expressed in E. coli, and purified.  Binding studies, including 
gel filtration and gel shift assays, were conducted. The results indicate that the mutations tested 
did not disrupt binding of the proteins of interest, so likely the mutagenized sites are not strongly 
involved in binding.  Future work should include examination of other possible binding sites in 
Sec9p. 
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BACKGROUND 
 
 
 
Exocytosis 
 
Exocytosis is an essential cellular function in which the cell secretes membrane-bound 
vesicles into the extracellular environment. Exocytosis (Figure 1) is necessary for the export or 
delivery of various molecules, including waste products, components of the extracellular matrix, 
various proteins (antibodies, enzymes, etc.), hormones and other lipids, and integral membrane 
proteins. Exocytosis is also employed to deliver and present antigens on the surface of the 
plasma membrane during an immune response.  Products destined for exocytosis are bound by 
vesicles pinched off from various organelles, including the endosomes, endoplasmic reticulum, 
Golgi apparatus, and lysosomes. The vesicles are trafficked to sites of secretion along the 
cytoskeleton or microtubules of the cell to their target destinations. Interestingly, despite the 
necessity of this process in numerous cellular activities, the regulation and mechanisms of 
exocytosis remain largely unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagram of Exocytosis.  The left section of the diagram 
denotes constitutive secretion, while the right section shows 
secretion triggered by calcium influx. 
http://cellbiology.med.unsw.edu.au/units/science/lecture0805.htm 
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Polarized Exocytosis 
 
Polarity is a vital element of cellular functions, from embryogenesis through apoptosis. 
Cell division, a highly regulated and polarized process, is necessary for embryonic development, 
cytokinesis, chromosome segregation, membrane growth, secretion activities, and cell fate 
determination. Exocytosis is also highly regulated and carefully polarized, as the trafficking of 
cargo to specific determinate sites is essential for cell survival. Examples of polarized exocytosis 
abound within the human body; correct polarization is essential for the trafficking of synaptic 
vesicles in the nervous system (Figure 2), or the secretion of waste products (in the form of 
sweat) from epithelial cells, or the secretion of gastric enzymes in the stomach, among other 
processes. 
 
 
Figure 2:  Vesicle Trafficking at the Neuronal Synapse. Diagram shows the exocytosis process 
used by neuro-muscular pre-synaptic neurons to release vesicles containing acetylcholine into the 
synaptic cleft.  (Bargmann, 2005) 
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Polarized exocytosis occurs in four distinct stages: trafficking, tethering, docking, and 
fusion. Trafficking involves the physical, directed movement of the vesicle from the organelle of 
origin to the site of secretion along microtubules or the cytoskeleton. This project focuses on the 
trafficking of vesicles from the Golgi apparatus along the actin cytoskeleton. The budding yeast 
Sacchromyces cerevisiae is used as a model experimental system. 
 
Yeast as a Model System 
 
Yeast is a particularly attractive model system for the study of exocytic regulation. This 
organism is the simplest eukaryote, and was the first to offer a completely sequenced genome 
(Dujon, 1996). Analysis of this completed genome has determined that S. cerevisiae, also known 
as budding yeast, contains significantly less non-coding DNA regions than higher eukaryotes. 
Higher eukaryotes often possess genomes containing complex regulatory elements that render 
genetic manipulation and analysis difficult. Yeast offer numerous advantages to other available 
model systems, including rapid growth, simple culture requirements, well-dispersed cells, ease of 
cell cycle regulation and synchronization, low cost of maintenance, and ease of genetic 
manipulation.  
Additionally, S. cerevisiae exhibits polarized growth, a characteristic that makes this 
organism useful for the study of polarized cellular processes (including exocytosis). This 
particular species of yeast buds in only one direction (Figure 3), as cell growth and secretion are 
localized to the bud tip only. Further, the actin cytoskeleton of budding yeast is highly polarized, 
running from the mother cell to the bud tip, parallel to the mother-bud axis (Pruyne et al., 1998). 
The class V myosin protein Myo2p serves as the ‘motor’ that traffics vesicles along the actin 
filaments to sites of secretion. Myo2p, coupled with the Rab protein Sec4p, facilitates the 
targeted movement and delivery of secretory vesicles from the mother body to the daughter bud 
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tip (Pruyne et al., 1998; Karpova et al, 2000). These characteristics make S. cerevisiae 
particularly useful for in vivo studies of polarized exocytosis. Vesicle delivery is easily 
visualized using fluorescence microscopy or similar techniques.  Further, yeast proteins may be 
recombinantly expressed in other systems (i.e. Escherichia coli), thereby aiding in vitro studies 
of exocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Photograph of the Budding of Sacchromyces cerevisiae as 
a Model of Polarized Exocytosis. 
http://pathmicro.med.sc.edu/mycology/yeast2.jpg 
 
 
 
 
The Exocyst Complex  
 
Vesicles are trafficked to sites of secretion along the cytoskeleton , and are ‘tethered’ to 
the plasma membrane by the multi-subunit exocyst complex (Figure 4). Tethering binds the 
vesicle in close enough proximity to the plasma membrane for SNARE complexes to form 
between SNARE proteins on the vesicle and the plasma membrane. As the SNARE complexes 
form, the two membranes are brought together to allow membrane fusion to take place. 
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Figure 4: The Exocyst Complex in S. cerevisiae.  The upper left diagram shows 
the directional budding of the yeast, with a vesicle targeted from the golgi 
apparatus to the cytoplasmic membrane within the bud.  The upper right diagram 
shows the exocyst complex tethering the vesicle to the membrane.  The lower 
diagram shows a closeup of the exocyst complex and its various proteins. 
Diagram courtesy of the Munson lab.  
www.umassmed.edu/faculty/graphics/208/Figure1.jpg 
 
 
The exocyst complex is an octameric protein complex conserved in all eukaryotes, and is 
essential in the tethering required for exocytosis and membrane growth. The complex is involved 
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in trans-Golgi network trafficking to the plasma membrane, and is composed of the subunits 
Sec3p, Sec5p, Sec6p, Sec8p, Sec10p, Sec15p, Exo70p, and Exo84p (shown in the figure, lower 
panel). These subunits appear to traffic to sites of secretion via secretory vesicles; at these sites, 
the complex tethers vesicles to the plasma membrane in preparation for membrane fusion. 
Crystallographic studies of four exocytic subunits (Sec15p, Exo70p, Exo84p, Sec6p) indicate 
that the subunits are rod-like helical bundle structures (Sivaram et al., 2006; Munson & Novick, 
2006). 
 
 
SNARE Proteins 
 
Soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) proteins 
are essential players in intracellular trafficking events. The SNARE proteins, found on the 
vesicle (v-SNAREs) and target membranes (t-SNAREs) in various pathways, these proteins 
assemble complexes necessary for subsequent membrane fusion. Most SNAREs are anchored to 
their respective membranes via C-terminal transmembrane domains (Sutton et al., 1998).  
SNARE complexes are formed by the specific interactions of v-SNAREs and t-SNAREs.  
Each SNARE complex is a parallel four-helix bundle (Sutton et al., 1998); the specificity of 
bundle assembly is dictated by the SNARE motif of each protein in the complex. The SNARE 
motif, a homologous 60-70 amino acid region forming a coiled coil domain, is responsible for 
the specificity of SNARE complex assembly via cognate protein pairing (Paumet et al., 2004).  
In the yeast trans-Golgi network (Figure 5), the SNARE complex is made up of the t-SNAREs 
Sso1p (red) and Sec9p (blue), both localized to the plasma membrane, and the v-SNARE Snc2p 
(green), which is localized to the vesicle membrane. 
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Figure 5: SNARE Complex Assembly in S. cerevisiae.  Figure from Nicholson 
et al., 1998. 
 
 
Sso1p and Snc2p each contribute one SNARE motif to the complex; the t-SNARE Sec9p 
contributes the two remaining motifs. SNARE proteins, like the exocyst, are conserved 
trafficking structures in eukaryotes. Sso1p, Snc2p, and Sec9p are homologous to the human 
SNAREs Synaptobrevin-II, Syntaxin-1A, and SNAP-25B, respectively (Figure 6). 
 
 
 
 
 
Figure 6: Domains of Human SNARE Proteins. 
http://www.cellsignal.com/reference/domain/snare.html  
 
 
Interactions Between Sec6p and Sec9p 
 
The exocyst subunit Sec6p is a predominantly helical, 88kD protein. Various mutant 
strains of this protein in S. cerevisiae exhibit the accumulation of secretory vesicles at the bud tip 
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at the restrictive temperature (37°C), indicating that the subunit is essential for the targeting of 
vesicles to sites of secretion (St. Pierre et al., 1994).  Recent studies (Songer & Munson, 2009) 
implicate Sec6 in the polarization of the other exocyst subunits to sites of secretion. This more 
recent work (Figure 7) found that patch mutants exhibited temperature sensitive growth. 
Interestingly, vesicles were still correctly trafficked to the plasma membrane; however, the intact 
exocyst complex was mislocalized.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The t-SNARE Sec9p, unlike other t-SNAREs, is not localized to sites of secretion 
(Brennwald et al., 1994). The C-terminal region of Sec9p (residues 416-651), homologous to 
human SNAP-25, has been used for Sec9p binding analysis in previous work (Sivaram et al., 
2005), and has been shown to have fully functional characteristics in vivo (Brennwald et al, 
Figure 7. Patch mutations in Sec6 result in proper vesicle 
trafficking, but mislocalization of the exocyst complex, at 
37°C.  Songer & Munson, 2008 
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1994).  This C-terminal construct, called Sec9CT, was used in this study to examine the potential 
Sec6p binding site in Sec9p. 
Previous work (Sivaram et al., 2005; Sivaram et al., 2006) established a direct interaction 
between the exocyst subunit Sec6p and the t-SNARE Sec9p. This published work characterized 
the structure of Sec6p, and established that the protein’s interaction with Sec9p inhibits the 
ternary complex assembly of the t-SNARE protein and its partner t-SNARE Sso1p. However, 
studies have not yet determined the Sec9p region responsible for Sec6p binding. 
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PROJECT PURPOSE 
 
 
The main goal of this project was to elucidate the region of the S. cerevisiae t-SNARE 
Sec9p responsible for the protein’s binding to the exocyst subunit Sec6p. A mutant Sec9 
construct (9KAKR) was cloned, expressed in E. coli, and purified in order to perform in vitro 
binding studies of the two proteins. The binding of Sec9p (and the 9KAKR mutant) to its partner 
t-SNARE, Sso1p, was also examined to ensure that the mutations made in Sec9p did not disrupt 
any other binding site.   
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METHODS 
 
Cloning 
 
To clone the Sec9 mutant necessary for this investigation, a truncated construct of Sec9p 
containing a C-terminal fragment (known as Sec9CT) was used.  Prior data gathered from 
Sec6/Sec9 cross-linking experiments (personal communication) suggested that the peptide 
QRKNVLEKAKRYQ in Sec9CT contained residues possibly essential for the binding to Sec6. 
A ‘patch’ of mutations in the KAKR peptide was determined to be a starting point for this 
project’s investigation. The residues in this 4-amino acid peptide (lysine, alanine, lysine, and 
arginine) were to be mutated to four alanine residues, as alanine is an uncharged amino acid, 
rendering the mutations far less likely to disturb the native structure of the Sec9CT protein.  
To create the mutant Sec9KAKR-AAAA (herein referenced as 9KAKR), two cloning 
primers were created:  
Forward primer: 9KAKR-AAAA-F  
5’ GGAAGAATGTTCTAGAAGCGGCAGCGGCATATCAGTTTGAG 3’ 
 
Reverse primer: 9KAKR-AAAA-R  
5’ CTCAAACTGATATGCCGCTGCCGCTTCTAGAACATTC 3’ 
 
Plasmid pLM-1 was selected to be the cloning vector for the 9KAKR mutant. The mutant 
was cloned into the vector in the EcoRI and BamHI restriction sites, using the following primers: 
5’ (EcoRI) primer: E-sec9ct 
5’ CGGAATTCTAAGGAGGATATTAAAATGG 3’ 
 
3’ (BamHI) primer: sec9ct-B 
5’ CGGGATCCCTATCTGATACCTGCC 3’ 
 
To ensure that proper cloning occurred, mutant DNA samples were sent for sequencing 
using the commercially available SP6 and T7 primers: 
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SP6 sequencing primer 
5’ ATTTAGGTGACACTATAG 3’ 
 
T7 sequencing primer 
5’ TAATACGACTCACTATAGGG 3’ 
 
 
Expression Trials 
 
Expression trials were necessary to determine if the 9KAKR mutant could be expressed 
in sufficient levels for protein purification. A volume of 1µL of the 9KAKR DNA was 
transformed into 100 µL of BL21 (DE3) Codon Plus competent E. coli cells, and incubated on 
ice for 1 hour. Cells were plated on LB (plus 1X carbenicillin and 1X chloramphenicol) plates, 
and grown overnight at 37°C. After overnight incubation, the cells were scraped from the plates 
into two 50mL starter cultures of LB media containing 1X ampicillin and 1X chloramphenicol. 
The starter cultures were grown at 37°C, shaking at 200 rpm, until they reached an OD600 of 0.6. 
At this density, 50 µL samples were taken for later gel analysis; the samples were spun down in a 
cold room centrifuge (13,200 rpm at 4°C), the pellets resuspended in 30 µL of 1X loading dye, 
and then boiled at 95°C for 5 minutes. The samples were stored at -20°C until gel analysis was 
performed. The starter cultures were inoculated with 0.1 mM and 0.3 mM (respectively) final 
concentrations of isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce protein expression, 
and grown for 3 hours at 37°C.  Post-induction samples were taken and prepared similarly to the 
pre-induction samples; 7 µL samples from both trial cultures were run on 15% SDS-PAGE gels. 
The gels were then stained with Coomassie Blue to visualize the protein in each sample to 
determine if the 9KAKR mutant expressed in levels similar to Sec9CT.  
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Growth and Purification of 9KAKR Protein 
 
To obtain purified 9KAKR protein, 1 µL of DNA was transformed into BL21 (DE3) 
Codon Plus competent cells, and allowed to incubate on ice for 1 hour. Cells were plated on LB 
(plus 1X carbenicillin and 1X chloramphenicol) plates, and grown overnight at 37°C. Cells were 
scraped into a 200 mL starter culture of LB media (plus 1X carbenicillin and 1X 
chloramphenicol), and grown at 37°C shaking at 200 rpm to an OD600 of 1.0.  Six liters of LB 
media (plus 1X carbenicillin) were inoculated, in equal volumes, with the starter culture, and 
allowed to grow to an OD600 of ~1. Cultures were induced at a final concentration of 0.1 mM 
IPTG, and grown another 3 hours at 37°C. Cells were harvested by spinning at 4°C, 5000 rpm in 
an Evolution centrifuge, scraping into appropriately sized conical tubes, and stored at -80°C.  
Cells were resuspended in cold Tris lysis buffer (pH 8), lysed in a cell disupter at 80 psi, 
and spun for 15 minute minutes at 5000 rpm in an Evolution centrifuge to pellet cell debris. The 
supernatant was removed, and placed into a glass beaker surrounded by ice. The supernatant was 
stirred slowly while approximately 5 mL of a 10% polyethyleneimine (PEI) solution was added; 
the PEI served to precipitate the nucleic acids remaining in the supernatant. An additional 100 
µL PMSF was added to the supernatant after the precipitation of nucleic acids was complete; the 
supernatant was spun as above to pellet the precipitated nucleic acids. After spinning, an 
additional 100 µL PMSF was again added. The supernatant (containing proteins) was filtered to 
remove any remaining particulates.  
The supernatant was loaded onto an 85 mL column volume Q Sepharose column pre-
equilibrated in a 10 mM Tris, pH 8, 50 mM NaCl buffer.  A secondary buffer (Buffer B: 10 mM 
Tris, pH 8; 1M NaCl) was also used to create a linear elution gradient. The protein was eluted 
from the column in 9 mL fractions over a 5-50% buffer B gradient, following a 2 column volume 
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(~170 mL) column wash. Samples from the chromatograph peaks were run on 15% 
polyacrylamide SDS-PAGE gels and stained with Coomassie Blue; those samples containing 
protein of the approximate correct size were pooled. 
To continue the purification process, ammonium sulfate was added to an 800 mM final 
concentration to the pooled solution. The solution was then loaded onto a pre-equilibrated 35 mL 
phenyl sepharose column; the column was  pre-equilibrated in a 43% buffer of 50 mM sodium 
phosphate, pH 7 (‘Buffer B’), and 53% Buffer A (50 mM sodium phosphate, pH 7; 1.4M 
ammonium phosphate). The column was eluted in 5 mL fractions over a 10 column volume 
(~350 mL) gradient from 43-100% Buffer B, following a 2 column volume (~70 mL) wash at 
43% Buffer B. Samples from the chromatograph peaks were run on 15% polyacrylamide SDS-
PAGE gels and stained with Coomassie Blue; those samples containing protein of the 
approximate correct size were pooled. 
The volume of pooled fractions totaled approximately 55 mL; this was concentrated to 8 
mL using a nitrogen spin concentrator, then brought to a total final volume of 50 mL with a 10 
mM Hepes buffer (pH 7.5). The volume of sample was then loaded onto a MonoQ 10/10 column 
pre-equilibrated in 10 mM Hepes buffer (pH 7.5). A secondary buffer (‘Buffer B’) was also used 
(10 mM Hepes, pH 7.5; 1M NaCl) to create a linear elution gradient. The column was washed 
with 2 column volumes of buffer at 5% Buffer B, then eluted over a 20 column volume gradient 
from 5-50% Buffer B.  Fractions were collected throughout (9 mL each during wash, and 2 mL 
each during elution). Samples from the chromatograph peaks were run on 15% polyacrylamide 
SDS-PAGE gels and stained with Coomassie Blue; those samples containing protein of the 
approximate correct size were pooled. 
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The pooled sample volume (approximately 39 mL) were concentrated with a nitrogen 
spin concentrator, and exchanged to potassium phosphate buffer (10 mM K2PO4, 10 mM 
KH2PO4, 140 mM KCl; pH 7.4) to a final volume of ~2.5 mL. The protein was then divided into 
150 µL aliquots and flash frozen in liquid nitrogen. The protein aliquots were stored at -80°C 
until use.  
 
Growth and Purification of Sec6N Protein 
 
BL21 (DE3) competent cells were transformed with 1 µL each of Sec6N DNA, incubated 
on ice for ~20 minutes, and plated on LB (plus 1X carbenicillin) plates. The plates were 
incubated at 37°C overnight. After overnight incubation, colonies were scraped into a starter 
culture of LB media (plus 1X ampicillin), and placed in an incubator shaking at 200 rpm for 1 
hour at 37°C. At an OD600 of ~1, the starter culture was evenly divided into six 1-liter bottles of 
LB media (plus 1X ampicillin), and incubated at 37°C, shaking at 200 rpm, until the OD600 
reached 0.4.  At this point, flasks were moved to 20°C and shaken at 200 rpm until the OD600 
reached 0.8.  The cultures were then induced with 0.1 mM IPTG (final concentration), and 
incubated at the same conditions for 3 hours. The cultures were spun down in an RC-3C 
centrifuge (4°C, 5000 rpm for 10 minutes); the supernatant was poured off, and the cells were 
scraped and frozen at -80°C until purification was performed.  
The cells were resuspended in approximately 300 mL of cold His lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole; pH 8. Fresh leupeptin, pepstatin, 5 mM (final) B-
mercaptoethanol, 1 mM (final) PMSF were added to the buffer just prior to cell lysis.). Cells 
were lysed using a cell disrupter at 80 psi, and spun for 30 minutes at 13000 rpm, 4°C, in an 
Evolution centrifuge. The supernatant was added to 6 mL of an Ni-NTA agarose bead slurry pre-
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equilibrated in His lysis buffer; beads were rocked on a Nutator at 4°C for 1 hour to allow 
binding of the His-tagged Sec6 protein to the beads. Beads were then spun at 800 rpm at 4°C for 
5 minutes, resuspended in a small volume of HIS lysis buffer, and poured into a BIO-RAD 
column to create a column bed. The bed volume of beads was then washed three times with a 
total of 18 mL of His wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole; pH 8. A 
fresh 5 mM final concentration of β-mercaptoethanol was added to the buffer just prior to 
washing). The beads were eluted with ten 3mL aliquots of His elution buffer (50 mM NaH2PO4, 
300 mM NaCl, 250 mM imidazole; pH 8. Fresh β-mercaptoethanol was again added just prior to 
elution) at 4°C. Each aliquot was collected as a separate fraction, and 5 µL of each was spotted 
onto Whatman paper; the Whatman paper was then stained with Coomassie Blue to determine 
which fractions contained protein.  
The fractions containing protein were pooled, filtered for aggregrates/particulate, and 
diluted to 50 mM NaCl.  This entire sample was loaded onto a MonoQ 10/10 column 
preequilibrated in 20% Buffer B (10 mM Tris, pH 8; 1M NaCl; 1 mM DTT). The column was 
eluted over a 20-60% gradient of Buffer B (where Buffer A was: 10 mM Tris, pH 8; 1 mM DTT) 
over 20 column volumes, with 0.5 mL fractions collected throughout. Fractions corresponding to 
chromatograph peaks indicated the elution of various proteins; samples from those fractions were 
run on 12% SDS-PAGE gels, and stained with Coomassie Blue.  
Those fractions containing protein were pooled, and loaded onto a Superose 200 16/60 
preparation-grade column (GE Healthcare) that was pre-equilibrated in potassium phosphate 
buffer (10 mM K2PO4, 10 mM KH2PO4, 140 mM KCl; pH 7.4. 1 mM DTT was added fresh to 
the buffer before column equilibration.). The column was eluted in 1mL fractions with potassium 
phosphate buffer. Samples from the fractions corresponding to chromatograph peaks were again 
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run on 12% SDS-PAGE gels. Those fractions corresponding to the purest Sec6 samples were 
pooled, yielding approximately 14.5 mL of sample. Using a spin nitrogen concentrator pre-
equilibrated with potassium phosphate buffer, this sample was concentrated down to 
approximately 0.85 mL in volume. Glycerol was added to the concentrated protein to a 10% final 
volume, along with a 1 mM final concentration of DTT; the protein was then divided into 50 µL 
and 100 µL aliquots, and flash frozen in liquid nitrogen. The protein aliquots were stored at  
-80°C until use.  
 
 
 
Determination of Protein Concentration: Ninhydrin Assay 
 
A ninhydrin assay was used to quantitatively determine the final concentration of the 
proteins used for this project. A 10 mM leucine standard was prepared, and an aliquot of the 
protein sample to be tested was thawed out and kept cold on ice. A series of dilutions (0 µL, 5 
µL, 7.5 µL, 10 µL, 12.5 µL, 20 µL) of the leucine standard was set up to create a standard curve 
for comparison; the same series of dilutions was used for the protein sample. A sample of 5 µL 
of filtered potassium phosphate buffer (10 mM K2PO4, 10 mM KH2PO4, 140 mM KCl; pH 7.4) 
was used for the 0 µL samples. These samples were added to polypropylene tubes containing 
0.15 mL 13N NaOH; the tubes were then covered with aluminum foil and autoclaved on the 
liquid cycle to hydrolyze the protein to amino acids. After autoclaving, the tubes were allowed to 
cool to room temperature before the addition of 0.25 mL glacial acetic acid, which was used to 
neutralize the hydrolysis reaction.  
A 0.4 mL volume of CN-ninhydrin solution was added to each reaction; the tubes were 
then loosely capped and placed in a water bath, where they were allowed to boil for exactly 15 
minutes. Immediately after boiling, 2mL of 50% isopropanol was added to each reaction. Each 
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tube was then tightly capped and shaken, then allowed to again cool to room temperature. The 
A570 of each sample was taken using a UV spectrophotometer, and a standard curve was created 
for each sample. The curve for the 10 mM leucine sample served as the standard/reference for 
the protein sample curve; the concentration of the protein sample in question was determined 
using the following formulas: 
 
(10mM)(slope of sample curve)      =   mM of amino acids 
(slope of leucine standard curve) 
 
         mM of amino acids                 =   mM of protein in sample 
# amino acids in protein sample 
 
 
 
Binding Assay I: Gel Filtration 
 
In order to quantitatively determine the Sec6/Sec9 interactions for this project, gel 
filtration runs of the proteins and their complexes were run using a Superose 200 10/30 
analytical column (GE Healthcare). 150 µL samples were prepared for each protein, each at a 10 
µM concentration per protein in the sample, in potassium phosphate buffer (10 mM K2PO4, 10 
mM KH2PO4, 140 mM KCl; pH 7.4). Complex samples were incubated at 18°C for the time 
period desired for binding examination, and the column pre-equilibrated in potassium phosphate 
buffer.  Samples were spun at 13,200 rpm in a cold room centrifuge (4°C) to pellet any 
precipitation or contaminates, then injected using a sterile 1mL syringe into a 100 µL loading 
loop.  Samples were loaded onto the gel filtration column using a 100 µL injection of potassium 
phosphate buffer through the loading loop; the column was then eluted in 0.5 mL fractions using 
potassium phosphate buffer. Absorbance at 280nm was used to determine protein elution from 
the column. 
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Binding Assay II: Gel Shift 
 
 In order to validate the results determined by gel filtration assay, native gels were used to 
examine the binding of Sec6/Sec9 in their native structures. 10 µL samples were prepared, with 
each protein at 10 µM concentration, in potassium phosphate buffer (10 mM K2PO4, 10 mM 
KH2PO4, 140 mM KCl; pH 7.4). Complex samples were incubated for 24 hours at 18°C; control 
samples were prepared fresh just prior to gel loading.  
Native gels (6% polyacrylamide) were pre-equilibrated at 4°C by running in 1X native 
gel buffer (10.75 mM imidazole, 8.75 mM Hepes; pH 7.4) at 30 mA for 15 minutes. A 2 µL 
volume of 6X native gel loading buffer was added to each sample prior to gel loading; 12 µL of 
each sample was loaded into gel wells (at the bottom, to prevent curved bands).  Gels were run at 
4°C for 45 minutes at 30 mA, then stained with Coomassie Blue to visualize the proteins. 
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RESULTS 
 
 
 
Purification of Sec9 9KAKR Mutant 
 
 The 9KAKR mutant was grown in E. coli, and the lysates purified over three preparatory 
columns using FPLC: an 85mL Q Sepharose column, a 35mL phenyl sepharose column, and a 
MonoQ 10/10 preparatory column. Several peaks were eluted from the Q Sepharose column 
(Figure 8); fractions corresponding to peak #5 (Figure 8, blue box) were pooled and prepared 
for loading onto the phenyl sepharose column as described in Methods.  
 
 
 
 
 
 
 
 
 
 
 
Three main protein peaks were eluted from the phenyl sepharose column (Figure 9), and 
fractions corresponding peak #2 (blue box) were pooled and prepared for loading onto the 
MonoQ 10/10 as described in Methods.  
Figure 8. Purification of 9KAKR, Column #1. This figure illustrates 
the chromatograph obtained from eluting the 85mL Q Sepharose 
column.  Fractions corresponding to peak #5 (blue box) were pooled 
and prepared for loading onto the phenyl sepharose column.   
1 
2 3 4 
5 
Fractions pooled 
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Two peaks eluted from the MonoQ 10/10 column; fractions containing >95% pure 
protein from peak #3 (Figure 10, blue box) were pooled and concentrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Purification of 9KAKR, Column #2.  This figure illustrates the 
chromatograph obtained from eluting the 35mL phenyl sepharose column. 
Fractions corresponding to the second peak (blue box) were pooled and 
prepared for loading onto the MonoQ 10/10 column.   
 
Fractions pooled 
Figure 10. Purification of 9KAKR, Column #3. This figure illustrates 
the chromatograph obtained from eluting the MonoQ 10/10 column. 
Fractions containing >95% pure protein (blue box) were pooled and 
concentrated.   
 
1 
2 
3 
Fractions pooled 
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Purification of Sec6N 
 
 Sec6N was purified over two preparatory columns using FPLC: a MonoQ 10/10 column, 
followed by a Superose 200 16/60 column. Two main peaks eluted from the MonoQ 10/10 
(Figure 11); fractions corresponding to peak #2 (red box) were pooled and prepared for loading 
onto the Superose 200 16/60, as described in Methods. 
  
 
 
 
 
 
 
 
 
 
     
 
 One main peak eluted from the Superose 200 16/60 column (Figure 12).  Fractions 
containing >95% pure protein (red box) were pooled and prepared for concentration, as 
described in Methods. 
 
 
 
 
 
 
 
Figure 11. Purification of Sec6N, MonoQ Column #1. This figure 
illustrates the chromatograph obtained from eluting the MonoQ 10/10 
column. The fractions corresponding to the second peak (red box) were 
pooled and prepared for elution over the Superose 200 16/60 column. 
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Gel Filtration is Sufficient for Separation of the Complexed Proteins of Interest 
 
 A Superose 200 10/30 gel filtration column was used to analyze interactions of purified 
Sec6p, Sec9p, Sso1p, and the 9KAKR mutant.  100 µL samples of each protein or complex were 
prepared at 10 µM concentrations; then complexes were incubated at 18°C for 24 hours. The 
samples were loaded onto the column in separate runs, and eluted from the column with 
potassium phosphate buffer, as described in Methods.  Analysis of the gel filtration runs for each 
individual protein indicated that the Superose 200 10/30 column was sufficient to differentiate 
the proteins of interest (Figure 13).  Thus, the resolution of this separation technique was 
sufficient to proceed with the mixing experiments.  Note that Sec9CT (red) and 9KAKR (green) 
absorb weakly due to their lack of phenylalanine residues.  
 
 
 
 
 
Figure 11. Purification of Sec6N, Column #1. This figure illustrates the 
chromatograph obtained from eluting the MonoQ 10/10 column. Fractions 
corresponding to peak __ were pooled and prepared for purification over the 
Superose 200 16/60 column. 
Figure 12. Purification of Sec6N, Column #2. This figure illustrates the 
chromatograph obtained from eluting the Superose 200 10/60 column. Fractions with 
>95% pure protein (red box) were pooled and concentrated.   
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Gel Filtration Assay: 9KAKR Mutant Binds to Sso1 
 
 100 µL samples of each purified protein or complex were prepared at 10 µM 
concentrations.  Samples of Sso1p/Sec9CT and Sso1/9KAKR were prepared to determine the 
ability of the 9KAKR mutant to bind to Sso1p in a manner similar to Sec9CT.  The complex 
samples were incubated at 18°C for 24 hours prior to gel filtration.  Samples were loaded and 
eluted individually.  Analysis of the gel filtration runs indicated that the 9KAKR mutant 
(turquoise) and Sso1p (green) individual proteins when mixed together (red) form a complex 
(left peak eluting with low retention volume) whose position is larger than either of the 
individual proteins alone.  The height of the 9KAKR/Sso1p complex is similar in size and mass 
to the complex formed by Sec9CT and Sso1p (dark blue, left peak) (Figure 14). 
 
 
 
 
 
Figure 13. Gel Filtration is Sufficient for Separation of 
Individual Proteins. This figure shows the difference in 
retention volume per protein tested. 
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Gel Filtration Assay: 9KAKR Mutant Binds to Sec6p  
 
100 µL samples of each protein or complex were prepared at 10 µM concentrations. 
Samples of Sec6/Sec9CT and Sec6/9KAKR were prepared in order to determine the ability of 
the 9KAKR mutant to bind to Sec6p in a manner similar to Sec9CT. The complex samples were 
incubated at 18°C for 24 hours prior to gel filtration. Samples were loaded and eluted 
individually.  Analysis of the gel filtration runs indicated that the 9KAKR mutant and Sec6p 
form a complex (purple, upper left curve) in a similar amount as Sec9CT and Sec6p (light blue, 
upper left curve) (Figure 15). 
 
 
 
 
 
 
 
 
Figure 14. The 9KAKR Mutant Does Not Disrupt Binding to Partner t-
SNARE Sso1p.  This figure demonstrates negligible differences in 
retention volume and peak absorbance for the Sso1/Sec9CT (dark blue) and 
Sso1/9KAKR (red) complexes.   
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Gel Shift Assay: 9KAKR Mutant Binds to Sec6  
  
 10 µL samples of proteins and samples were prepared at 10 µM concentrations; complex 
samples were incubated for 24 hours at 18°C.  Samples were loaded onto a 6% polyacrylamide 
native gel, which was run at 4°C to separate the proteins and complexes. Analysis of the results 
by gel shift assay indicated that the 9KAKR mutant binds to Sec6p (center red circle) and Sso1p 
(right red circle) in a manner similar to Sec9CT, as indicated by the similar mobilities of the 
complex pairs in the native gel (Figure 16).  However, 9KAKR exhibits different gel mobility 
than Sec9CT (left red circle) (Figure 16).  
 
 
 
 
 
 
 
 
Figure 15. The 9KAKR Mutant Does Not Disrupt Binding to Exocyst 
Subunit Sec6p. This figure demonstrates negligible differences in retention 
volume and peak absorbance for the Sec6/Sec9CT (light blue) and 
Sec6/9KAKR (purple) complexes.   
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Figure 16. Gel Mobility Assay. 9KAKR exhibits shift in 
mobility, but does not disturb binding to Sec6p or Sso1p. 
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DISCUSSION 
 
 
 This study aimed to examine the in vitro effects of a Sec9p ‘patch’ mutant, 9KAKR, on 
the binding of the Sec9 t-SNARE to the exocyst subunit Sec6p.  Previous work in the Munson 
lab suggested a role of Sec6p in the regulation of SNARE complex assembly at the plasma 
membrane (Sivaram et al., 2005; Sivaram et al., 2006), however, the binding site for Sec6p was 
not determined in Sec9p. The 9KAKR mutant was designed to disturb residues in a peptide 
region (Appendix B) suspected to play a role in Sec6/Sec9 binding, as suggested by cross-linking 
experiments and mass spectrometry (Munson, personal communication). The residues KAKR 
were mutated to a patch of four alanine residues in order to create an uncharged ‘pocket’ that 
would potentially disrupt binding, but not disrupt the proper folding of the protein. The mutant 
was cloned, recombinantly expressed in E.coli, and purified using FPLC, and its interactions 
with Sec6 tested in vitro using gel filtration and gel shift assays.  
 
 All protein complex samples were incubated at 18°C for 24 hours prior to analysis by 
each method. These parameters had been used in previous examinations of Sec6/Sec9 binding 
(Sivaram et al., 2005), and were kept the same for the sake of continuity. Further, the t-SNARE 
Sso1 exhibits a closed conformation that requires opening time in vitro for the binding to Sec9 to 
occur (Munson et al., 2000). Complete complex formation requires approximately 48 hours in 
vitro for these two proteins; the 24 hour incubation time was selected in order to visualize each 
uncomplexed individual protein in the complex in addition to complex assembly (Figure 16).  
 
 Gel filtration separates proteins according to their relative sizes; smaller proteins diffuse 
into the porous beads of gel filtration columns and take greater time to elute from the column 
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than larger proteins, which do not diffuse as easily. The 9KAKR mutant was not a truncation or 
expanded construct of Sec9CT, and eluted from the gel filtration column similarly to Sec9CT 
(Figure 10).  The low absorbance of the Sec9CT and 9KAKR constructs can be attributed to the 
residues in each protein; the analysis of eluted proteins using FPLC was taken at 280nm, and 
since the Sec9CT and 9KAKR constructs do not contain phenylalanine residues, they do not 
absorb well at that particular wavelength.  However, the results indicated that the gel filtration 
column provided sufficient resolution to separate the complex and individual proteins of interest 
for this project (Figure 13).  
 
 Gel filtration analysis of 9KAKR binding to Sec6p and Sso1p indicated that the 
mutations made did not disrupt binding to the partner t-SNARE or to the exocyst subunit 
(Figures 14 and 15).  In each case, the results of the complex samples for the 9KAKR construct 
were compared to the complex samples of Sec9CT. Complex formation is indicated by a shift in 
elution volume; since complexes are larger in size, they elute from the gel filtration column more 
quickly than the proteins within them. The results demonstrate that the 9KAKR mutant was not 
sufficient to disrupt binding to Sec6p or Sso1p; further, the mutant binds to Sec6p and Sso1 in a 
manner that forms the same amount of complex as Sec9CT.  
 
 Gel shift assays were used to determine the in vitro binding of 9KAKR while 
demonstrating if any structural changes occurred due to the mutations made. The data suggests 
that the 9KAKR mutant has a difference in structure, pH, or another characteristic in comparison 
to Sec9CT, as the two proteins exhibit different mobilities within the native gel (Figure 16). 
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Interestingly, there is also a shift in the formation of complex with Sso1p, again suggesting a 
change in some physical characteristic of the 9KAKR mutant. 
 
Recommendations for Future Work 
 The data collected during this project suggest that the peptide sequence of interest 
(Appendices A & B) may not be the Sec6p binding region in Sec9p. However, this conclusion 
should be considered carefully due to the significant shift in mobility of the 9KAKR mutant as 
compared to Sec9CT in the gel shift assays performed.  Should interested parties wish to pursue 
this mutant further, structural analysis (ex. circular dichroism) of the 9KAKR construct should 
be performed to analyze its native structure. This analysis would shed light on the construct’s 
conformation and enable the determination of whether the mutations made disrupted proper 
folding.  Other possible binding sites in Sec9p should also be pursued, as it is possible that other 
residues in the peptide region are more influential in binding to the exocyst. It may also be 
possible that the peptide region itself is wrong – examination of other regions in Sec9p should be 
undertaken as well. 
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Appendix I. Amino Acid Sequence of Sec9p 
 
 
Note that the highlighted peptide region (QRKNVLEKAKRY) was the region of interest for the 
Sec6/Sec9 binding site. 
 
 
MGLKKFFKIKPPEEATPEQNKDTLMELGISVKNPSKKRKE KFAAYGKFAN 
DKAEDKVYAPPGYEQYARPQDELEDLNASPLDANANEATAGSNRGSSGTQ 
DLGNGAESNSMQDPYAIENDDYRYDDDPYARFQANKSNGRGSVNAAPYGD 
YGGGYNGTSLNSYNNDGPYSNQNTSNSWVNANGRNSLNHSNSTLNVGPSR 
QTRQPPVSTSTNSLSLDQRSPLANPMQEKRNPYADMNSYGGAYDSNTNRS 
SGTRQGSSKNANPYASMANDSYSNGNLNRSANPYSSRSVRQPQSQQAPMT 
YTPSFIASDEAARNSEVDLNEEPRTGEFDFEEVYADKSAENRAALDEPDL 
NAVMTNEDSIDLNASEVDHSSRQQQQQQWFMDEQQQQQQHFNATNNQYGD 
QRGYKTFEEIQKEEEARQQQEEDEAVDEIKQEIKFTKQSSVASTRNTLKM 
AQDAERAGMNTLGMLGHQSEQLNNVEGNLDLMKVQNKVADEKVAELKKLN 
RSILAVHVSNPFNSKRRRREREEQLKNRKI EEKLMREQTSQQLSQSTQRI 
EGAMNANNNISEVRERYQRKNVLEKAKRYQFENDEEDDEMELEIDRNLDQ 
IQQVSNRLKKMALTTGKELDSQQKRLNNIEESTDDLDINLHMNTNRLAGI R 
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Appendix II. Amino Acid Sequence of Sec9CT 
 
 
Note that the highlighted peptide region (QRKNVLEKAKRY) was the region of interest for the 
Sec6/Sec9 binding site. 
 
 
MARQQQEEDEAVDEIKQEIKFTKQSSVASTRNTLKMAQDAERAGMNTLGMLG
HQSEQLNNVEGNLDLMKVQNKVADEKVAELKKLNRSILAVHVSNPFNSKRRR
REREEQLKNRKIEEKLMREQTSQQLSQSTQRIEGAMNANNNISEVRERYQRKN
VLEKAKRYQFENDEEDDEMELEIDRNLDQIQQVSNRLKKMALTTGKELDSQQ
KRLNNIEESTDDLDINLHMNTNRLAGIR 
 
 
